Veracyte, Inc. (VCYT) Financials
VCYT Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 1.1 billion | 93.7 million |
| 2023-09-30 | 1.1 billion | 70.9 million |
| 2023-06-30 | 1.2 billion | 78.4 million |
| 2023-03-31 | 1.2 billion | 75.9 million |
VCYT Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 13.1 million | 7.5 million |
| 2023-09-30 | 11.4 million | 7.3 million |
| 2023-06-30 | 13.0 million | 10.4 million |
| 2023-03-31 | -3.2 million | 8.0 million |
VCYT Net Income
No data available :(
VCYT Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 216.5 million | - | 12.6 million |
| 2023-09-30 | 202.5 million | - | 13.7 million |
| 2023-06-30 | 191.1 million | - | 14.9 million |
| 2023-03-31 | 177.9 million | - | 13.8 million |
VCYT Shares Outstanding
VCYT Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 2.5 million | 18.4 million | 41.1 million | 7.1 million |
| 2023-09-30 | 2.8 million | 13.3 million | 16.3 million | 24.3 million |
| 2023-06-30 | 3.7 million | 12.5 million | 25.0 million | 25.8 million |
| 2023-03-31 | 993000 | 12.8 million | 22.5 million | 26.1 million |
VCYT Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 98.2 million | 35.0 million |
| 2023-09-30 | 90.1 million | 27.6 million |
| 2023-06-30 | 90.3 million | 29.7 million |
| 2023-03-31 | 82.4 million | 26.2 million |
VCYT
Price: $20.35
52 week price:
Payout Ratio Range:
Earnings Per Share: -1.02 USD
P/E Ratio: -35.43
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 321710
Ebitda: -5.2 millionMarket Capitalization: 1.5 billion